Literature DB >> 27490017

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.

Yu Zhang1, Lieping Chen2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27490017      PMCID： PMC5492376          DOI： 10.1001/jamaoncol.2016.2450

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  7 in total

1.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

Review 2.  Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

Review 3.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

Review 4.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

Authors:  Lieping Chen; Xue Han
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 5.  Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Authors:  Evan J Lipson; Patrick M Forde; Hans-Joerg Hammers; Leisha A Emens; Janis M Taube; Suzanne L Topalian
Journal:  Semin Oncol       Date:  2015-06-10       Impact factor: 4.929

Review 6.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

7.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  7 in total
  54 in total

1.  Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

Authors:  Tsuyoshi Hamada; Yin Cao; Zhi Rong Qian; Yohei Masugi; Jonathan A Nowak; Juhong Yang; Mingyang Song; Kosuke Mima; Keisuke Kosumi; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Edward L Giovannucci; Marios Giannakis; Scott J Rodig; Gordon J Freeman; Daniel Nevo; Molin Wang; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino
Journal:  J Clin Oncol       Date:  2017-04-13       Impact factor: 44.544

Review 2.  Biomarker for personalized immunotherapy.

Authors:  Si-Yang Liu; Yi-Long Wu
Journal:  Transl Lung Cancer Res       Date:  2019-11

3.  High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Authors:  Maria I Toki; Christopher R Merritt; Pok Fai Wong; James W Smithy; Harriet M Kluger; Konstantinos N Syrigos; Giang T Ong; Sarah E Warren; Joseph M Beechem; David L Rimm
Journal:  Clin Cancer Res       Date:  2019-06-12       Impact factor: 12.531

4.  Predictive immune biomarkers: an unattainable chimera?

Authors:  Anna Maria Trotta; Roberto Pacelli; Stefania Scala
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

Review 5.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

Review 6.  Defining and Understanding Adaptive Resistance in Cancer Immunotherapy.

Authors:  Tae Kon Kim; Roy S Herbst; Lieping Chen
Journal:  Trends Immunol       Date:  2018-05-22       Impact factor: 16.687

7.  Overview of Lung Cancer Immunotherapy.

Authors:  Miguel F Sanmamed; Iñaki Eguren-Santamaria; Kurt A Schalper
Journal:  Cancer J       Date:  2020 Nov/Dec       Impact factor: 3.360

8.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

9.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

10.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.